ReCode Therapeutics logo

ReCode Therapeutics Funding & Investors

ReCode Therapeutics is an integrated genetic medicines company developing targeted, disease-modifying therapies for patients with life-limiting respiratory diseases.

recodetx.com

Total Amount Raised: $521,799,392

ReCode Therapeutics Funding Rounds

  • Series Unknown

    $10,000,000

    Series Unknown Investors

    Cystic Fibrosis Foundation
  • Series B

    $120,000,000

    Series B Investors

    Matrix Capital Management
    Pfizer Venture Investments
    Sanofi Ventures
    Leaps by Bayer
    Amgen Ventures
  • Series B

    $259,799,396

    Series B Investors

    Colt Ventures
    Superstring Capital
    EcoR1 Capital
    Tekla Capital Management
    Hunt Technology Ventures
    Vida Ventures
    Osage University Partners
    MPM Capital
    Pfizer Venture Investments
    NS Investment
    Sanofi Ventures
    OrbiMed Advisors
  • Series A

    $80,000,000

    Series A Investors

    Colt Ventures
    Hunt Technology Ventures
    Vida Ventures
    Osage University Partners
    MPM Capital
    OrbiMed Advisors
  • Series B

    $50,000,000

    Series B Investors

    EcoR1 Capital
    Vida Ventures
    Matrix Capital Management
    Osage University Partners
    MPM Capital
    Solasta Ventures
    Pfizer Venture Investments
    Sanofi Ventures
    Leaps by Bayer
    OrbiMed Advisors
    Amgen Ventures
    Bioluminescence Ventures
  • Seed

    $2,000,000

Funding info provided by Diffbot.